Dr. Redfield Breaks His Silence — Long COVID, Cancer & Vaccines [And Chronic Lyme]
So it looks like Redfield is now a Scientific Advisor for TechImmune, LLC.
That vaccine money grab through patent royalties or advisory roles is just too lucrative to pass up.
From the TechImmune website: https://techimmune.com/
“TechImmune, LLC has been awarded a business (SBIR) grant from the U.S. National Institute of Allergy and Infectious Diseases (NIH) to develop a Universal Vaccine Against Multiple Coronavirus Variants of Concern. Additional grants are pending.”
Scientific Advisor
Dr. Redfield is the former Director of the Centers for Disease Control and Prevention and a distinguished public health leader with decades of experience in medicine and research. He played a key role as a contributor to Operation Warp Speed, helping accelerate the development of life-saving vaccines [Huh???] during the COVID-19 pandemic. Today, he continues to advance the field through his active involvement in Long COVID clinical research.
Please see my email to Dr Redfield following his interview from the Dana Parish Podcast.
(Picture of Redfield was found here)
———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “rrredfieldmd@gmail.com” <rrredfieldmd@gmail.com>
Cc: dana@danaparish.com, sephillips18@gmail.com, skottilil@ihv.umaryland.edu
Date: 11/06/2025 10:39 AM EST
Subject: The Dana Parish Podcast; Dr. Redfield Breaks His Silence — Long COVID, Cancer & Vaccines [And Chronic Lyme]
The Dana Parish Podcast
Dr. Redfield Breaks His Silence — Long COVID, Cancer & Vaccines [And Chronic Lyme]
http://
Excerpt:
Dana Parish: “Why are we still suffering like this… it is known at the upper echelons of Public Health that Lyme is chronic.”
Dr. Redfield: “Cause people can’t get a simple diagnostic test to prove it.”
Institute of Human Virology, University of Maryland
725 West Lombard St, Room N560
Baltimore, MD 21201
Dr. Redfield,
You are mistaken. The real reason why “we are still suffering” is outlined in the correspondence below addressed to Adrian Duncan, Group Vice President of WebMD referencing their latest CME offering for Lyme disease. Google’s Gemini AI describes it as: intent to deceive for financial gain.
Carl Tuttle
Independent Researcher
Hudson, NH USA
Cc: Shyamasundaran Kottilil, MBBS, PhD
Institute of Human Virology, Director, Clinical Care & Research; Chief, Infectious Diseases; Professor of Medicine
Email sent to Adrian Duncan, Group Vice President WebMD:
#1 ——— Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: aduncan@webmd.net
Cc: cme@medscape.net, caitlin@medlitera.com, naseem@medlitera.com, michelle@medlitera.com
Date: 10/24/2025 12:42 PM EDT
Subject: Medscape Now! Understanding the Latest Evidence and Best Practices for Interprofessional Care of Post-Treatment Lyme Disease Syndrome
Medscape Now! Understanding the Latest Evidence and Best Practices for Interprofessional Care of Post-Treatment Lyme Disease Syndrome
https://www.medscape.org/viewarticle/medscape-now-understanding-latest-evidence-and-best-2025a1000rrr
CME Author: Naseem Bazargan, MPH Developed with AI assistance.
Excerpt:
State of the Evidence
“To date, our understanding of the pathophysiology of Lyme IACI remains limited,[4] with little to no evidence supporting chronic Borrelia infection as the underlying cause.”
Adrian Duncan, Group Vice President
Global Head of Education & Medical Affairs
Dear Mr. Duncan,
In reference to the Medscape article written by Naseem Bazargan, I asked Google’s Gemini AI the following questions:
The latest Medscape CME education claiming to be developed with AI assistance, appears to have omitted the following references:
2018 Middelveen study; “Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease” identifying twelve patients who were culture positive after antibiotic treatment. Some of these patients had taken as many as eleven different types of antibiotics. Also missing is the NIH funded Embers studies of persistent Bb infection in monkeys and mice. And the Sapi study: “The Long-Term Persistence of Borrelia burgdorferi Antigens and DNA in the Tissues of a Patient with Lyme Disease” Here is the positive culture report from the CDC at Fort Collins Colorado and the chronic Lyme autopsy results from the patient in the Sapi study: Page 1, 2, 3, 4, 5, 6, 7. The destructive nature of Borrelia is evident in the patient’s liver (nutmeg liver), kidneys, heart, lungs and brain. The patient died after the insurer refused additional IV antibiotic therapy.
Additional reference from 1990: “Chronic neurologic manifestations of Lyme disease” Dr. Allen Steere
In fact, there appears to be 700 references identifying persistent infection.
Question: So, is AI participating in the collusion to suppress evidence of antibiotic resistance or chronic Lyme disease? And what about the other 700 references identifying persistent infection?
Mr. Duncan… I will spare you the lengthy discourse and get right to the point.
Questions to AI:
1. Does a chronic relapsing seronegative disease fit the vaccine model?
AI Response:
A chronic, relapsing, seronegative disease does not fit the traditional vaccine model, which is primarily designed to prevent initial infections. The characteristics you describe present significant scientific and commercial challenges for vaccine developers.
2. Since you agreed that a chronic, relapsing, seronegative disease does not fit the traditional vaccine model this in and of itself would be the motivation to conceal any and all evidence of persistent infection wouldn’t you agree? This so-called debate is not a debate at all and deserves a criminal investigation. Who would be a suitable candidate to approach for a legal case?
AI Response: Allegations of medical fraud are typically handled as civil matters, but they can become criminal if there is evidence of gross negligence, recklessness, or intent to deceive, especially for financial gain.
Mr. Duncan,
Thirty-four years ago Dr. Allen Steere identified chronic Lyme disease which should have set off a red flag prompting an immediate search for better antimicrobials but then did a 180° as he became principal investigator (PI) of the Phase 3 clinical trial for the first Lyme disease vaccine. So all the eggs were put into the vaccine basket while a campaign was orchestrated to discredit the sick and disabled patient population along with the courageous clinicians attempting to help these patients. Apparently, a chronic relapsing seronegative disease did not fit the business model of patent royalties, vaccine development and pharmaceutical profits. This set the stage for long-term treatment denial and unimaginable pain and suffering around the world. It has been ongoing for over three decades now and the latest CME from Medscape is propagating this travesty.
Lyme disease has been grossly mishandled by our public health officials for the sake of a vaccine. A false public health narrative was enforced and any clinician who did not follow that narrative risked losing their license to practice medicine as seen in the documentary: Under our Skin. (please watch the 5min trailer)
I want to make this crystal clear; suppressing evidence of antibiotic resistance is not collaboration, it is collusion. Will you turn a blind eye to the facts/evidence I have presented?
A response to this inquiry is requested.
Respectfully submitted,
Carl Tuttle
Independent Researcher
Hudson, NH USA
Additional references:
Evidence Of Persistence Of Lyme Disease In Humans
https://www.lymedisease.org/lyme-basics/resources/evidence-of-persistence-lyme-disease-in-humans/
#2 ———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>To: aduncan@webmd.netCc: cme@medscape.net, caitlin@medlitera.com, naseem@medlitera.com, michelle@medlitera.comDate: 10/28/2025 9:28 AM EDT
Subject: Re: Medscape Now! Understanding the Latest Evidence and Best Practices for Interprofessional Care of Post-Treatment Lyme Disease Syndrome
Dear Mr. Duncan,
In 2016 Dr. Paul Auwaerter, past president of the Infectious Diseases Society of America coauthored a study revealing the persister form of Borrelia burgdorferi resistant to antibiotics.
Here is a timeline of events:
2015
Standard antibiotic treatment for Lyme disease does not kill persistent Borrelia bacteria.
http://droopyyoupi.blogspot.com/2015/08/standart-antibiotic-treatment-for-lyme.html
Excerpt:
-What has tuberculosis and Borrelia burgdorferi in common? In the late stage of the disease occurs persistent (tolerant) bacteria, which essentially means that the bacteria lasts and lasts and lasts. They protect themselves against antibiotics and are difficult to treat.
– Both Borrelia burgdorferi and tuberculosis is relatively easy to cure in the early stages, even with the use of one antibiotic. In the late stage it is impossible to cure the disease with the same type of treatment in the acute phase, said Dr. Ying Zhang when he visited the year NorVect conference.
-Dr. Ying Zhang is a professor at the Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health
-Two days after NorVect conference, published Dr. Ying Zhang’s latest research Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection.
2016
A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library Jie Feng 1, Wanliang Shi 1, Shuo Zhang 1, David Sullivan 1, Paul G Auwaerter 2, Ying Zhang 1
https://pubmed.ncbi.nlm.nih.gov/27242757/
Abstract
Under experimental stress conditions such as starvation or antibiotic exposure, Borrelia burgdorferi can develop round body forms, which are a type of persister bacteria that appear resistant in vitro to customary first-line antibiotics for Lyme disease. To identify more effective drugs with activity against the round body form of B. burgdorferi, we established a round body persister model induced by exposure to amoxicillin (50 μg/ml) and then screened the Food and Drug Administration drug library consisting of 1581 drug compounds and also 22 drug combinations using the SYBR Green I/propidium iodide viability assay. We identified 23 drug candidates that have higher activity against the round bodies of B. burgdorferi than either amoxicillin or doxycycline.
2022
Nitroxoline Drug Combinations Are More Active Than Lyme Antibiotic Combination and Can Eradicate Stationary-Phase Borrelia burgdorferi
Alvarez-Manzo, Hector S.1; Zhang, Yumin1; Zhang, Ying2,✉
https://journals.lww.com/imd/fulltext/2022/09000/nitroxoline_drug_combinations_are_more_active_than.7.aspx
Abstract
Lyme disease (LD), caused by Borrelia burgdorferi, is the most common vector-borne disease in the United States and Europe. Despite the standard 2–4 weeks’ antibiotic treatment, approximately 10%–20% of patients will develop posttreatment LD syndrome, a condition that is poorly understood. One of the probable causes is thought to be the presence of B. burgdorferi persister forms that are not effectively killed by the current LD antibiotics. In this study, we evaluated nitroxoline, an antibiotic used to treat urinary tract infections, for its activity against a stationary-phase culture enriched with persister forms of B. burgdorferi. Nitroxoline was found to be more active than doxycycline and equally active as cefuroxime (standard LD antibiotics) against B. burgdorferi. Importantly, the nitroxoline two-drug combinations nitroxoline + cefuroxime and nitroxoline + clarithromycin, as well as the nitroxoline three-drug combination nitroxoline + cefuroxime + clarithromycin, were as effective as the persister drug daptomycin-based positive control three-drug combination cefuroxime + doxycycline + daptomycin, completely eradicating stationary-phase B. burgdorferi in the drug-exposure experiments and preventing regrowth in the subculture study. Future studies should evaluate these promising drug combinations in a persistent LD mouse model.
Dr. Redfield… This is the missing research that should have been conducted early in the discovery phase of the disease but as we now know, all the eggs were put into the vaccine basket while a campaign was orchestrated to discredit the sick and disabled patient population along with the courageous clinicians attempting to help these patients. What has been deceitfully established here in the US is wreaking havoc globally. Example: Lyme disease: Australians ‘being treated worse than a dog riddled with mange’, Senator John Madigan says
https://www.abc.net.au/news/2016-01-11/lyme-disease-treatment-in-australia-criticised-by-john-madigan/7080708
This research is being suppressed as the disabled Lyme patient population around the globe remain sick indefinitely. (Three decades and counting)
Guideline signatory Dr. Raymond Dattwyler owns 24 patents for Lyme disease that include diagnostic testing and vaccines both live bacteria and oral and endorses the categorical assertion that chronic Lyme disease does not exist yet his patent for novel chimeric nucleic acids and protein antigens which could serve as a basis for a vaccine or for improved immunodiagnostic reagents for Lyme disease, issuing almost contemporaneously with the 2006 IDSA Lyme Disease Guidelines seems to say exactly the opposite:
“Currently, Lyme Disease is treated with a range of antibiotics, e.g. tetracycline, penicillin and cephalosporins. However, such treatment is not always successful in clearing the infection. Treatment is often delayed due to improper diagnosis with the deleterious effect that the infection proceeds to a chronic condition, where treatment with antibiotics is often not useful. One of the factors contributing to delayed treatment is the lack of effective diagnostic tools.” (Dattwyler, et.al. United States Patent 7,179,448)
Please take a moment if you will to review the following inquiry addressed to doctor Dattwyler who has set the stage for long-term treatment denial. It should be noted that there was no response.
———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: Raymond_Dattwyler@nymc.edu
Cc: npjvaccines@nature.com, abarrett@utmb.edu, R.W.Titball@exeter.ac.uk, mgomesso@uthsc.eduDate: 01/06/2023 2:46 PM EST
Subject: The year that shaped the outcome of the OspA vaccine for human Lyme disease
npj Vaccines Jan 2022
The year that shaped the outcome of the OspA vaccine for human Lyme disease
https://www.nature.com/articles/s41541-022-00429-5 Raymond J. Dattwyler & Maria Gomes-Solecki
Department of Microbiology and Immunology
New York Medical College
Valhalla, NY
Raymond J. Dattwyler, Corresponding Author
Dear Dr. Dattwyler,
I read your manuscript with great interest as you call attention to a treatment-resistant Lyme arthritis with “no evidence of DNA” found in the joints of patients after antibiotic treatment.
For some strange reason however, I could not find the following 1995 publication within your paper identifying treatment-resistant neuroborreliosis:
European Neurology 1995
Seronegative Chronic Relapsing Neuroborreliosis
https://www.karger.com/Article/Abstract/117104
Lawrence C., Lipton R.B., Lowy F.D., Coyle P.K.d
Abstract
We report an unusual patient with evidence of Borrelia burgdorferi infection who experienced repeated neurologic relapses despite aggressive antibiotic therapy. Each course of therapy was associated with a Jarisch-Herxheimer-like reaction. Although the patient never had detectable free antibodies to B. burgdorferi in serum or spinal fluid, the CSF was positive on multiple occasions for complexed anti-B. burgdorferi antibodies, B. burgdorferi nucleic acids and free antigen.
In fact, Dr. Dattwyler there seems to be a great deal of “treatment-resistant” evidence published in multiple journals over the past three decades:
Peer Reviewed Evidence of Persistence of Lyme Disease Spirochete Borrelia burgdorferi and Tick-Borne Diseases (700 References)
https://www.dropbox.com/s/n09sk90eo6xz7ua/700%20articles%20LYME%20EvidenceofPersistence-V2.pdf?dl=0
So that brings me to the reason for this email…
Question:
Does a chronic relapsing seronegative disease fit the vaccine model? If not, would that, in and of itself, be the hidden reason for denying chronic (treatment-resistant) Lyme disease for almost three decades? In other words, patent royalties and pharmaceutical profits over lifesaving care?
A response to this inquiry is requested.
Carl Tuttle
Hudson, NH
Cc: Alan D.T. Barrett, PhD Editor-in-Chief
Rick Titball, PhD, DSc, Deputy Editor
Letter to the Editor of the BMJ published June 2020
https://www.bmj.com/content/369/bmj.m1041/rr-1
Dr. Redfield… We have been dealing with an antibiotic resistant/tolerant super-bug. Post Treatment Lyme Disease Syndrome (PTLDS) is simply a fabricated medical condition disguising treatment failure. A chronic relapsing seronegative disease DOES NOT fit the vaccine model because you cannot prove vaccine efficacy in a disease where we don’t know who has or does not have the infection! So, deny the chronically infected by suppressing all evidence of antibiotic resistance, claim that the infection is easily treated because newer curative treatment for all stages of disease would give the public an excuse not to take the vaccine, reject all direct-detection methods that prove chronic infection and voila! move forward with patent royalties, vaccine development and pharmaceutical profits. The federal watchdog is no more. People suffering and dying and for what? Lyme for Profit.
The CDC has propagated this false Lyme disease narrative for decades and to this day refuses to recognize the disabling stage of the disease exposed in the documentaries Under our Skin and The Quiet Epidemic.
You may want to read the following Newsweek article published April 2024 by Lindsay Keys Co-Director of The Quiet Epidemic as it describes precisely what affect suppressing/concealing antibiotic resistance has had on the patient population…
Lyme Disease Is Quietly Debilitating Millions of Americans and Future Generations | Opinion
https://www.newsweek.com/lyme-disease-quietly-debilitating-millions-americans-future-generations-opinion-1885764
Excerpt:
Lyme costs the U.S. an estimated $1 billion annually. Chronic Lyme patients are going bankrupt, suffering from job loss, and experiencing high rates of suicide. The history of Lyme has been plagued with controversy—a National Institutes of Health (NIH) official once referred to patients as “Lyme loonies.” Given the widespread suffering and economic burden, we were shocked to discover Lyme diagnostics and treatments have not advanced since the 1990s. Due to a lack of research, the mainstream medical community resorts to telling people it’s in their heads.
Carl Tuttle
Independent Researcher
Hudson, NH USA
Madison Area Lyme Support Group 